Dexamethasone is recommended by the NIH and the World Health Organization for treating COVID-19.
Amneal has launched dexamethasone, 4 mg and 6 mg, a generic version of Decadron, an anti-inflammatory glucocorticoid steroid used to treat several medical conditions, including respiratory complications associated with COVID-19.
Dexamethasone is recommended by the NIH and the World Health Organization for treating COVID-19. In the RECOVERY trial, dexamethasone was shown to reduce mortality in hospitalized patients with COVID-19 who required supplemental oxygen. This study was published in the New England Journal of Medicine in February 2021.
But dexamethasone tablets can produce reversible hypothalamic-pituitary adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency. The HPA is complex system of neuroendocrine pathways that function to maintain physiological homeostasis. Changes in this system can potentially lead to a disruption in neuroendocrine, behavioral, autonomic, and metabolic function
Elevated blood pressure, sodium and water retention, and increased excretion of potassium, have also been reported.
Mild-to-severe infection with exacerbation may occur with the use of dexamethasone tablets alone or in combination with other immunosuppressive agents. Dexamethasone is contraindicated in patients hypersensitive to any components of this product.
AstraZeneca, Daiichi Sankyo Submit New BLA for Datopotamab in Lung Cancer
November 12th 2024After feedback from the FDA, the companies have voluntarily withdrawn the previous biologics licensing application for datopotamab deruxtecan for patients with advanced or metastatic nonsquamous non-small cell lung cancer.
Read More
Skyrizi Overtakes Humira in U.S. Sales Numbers
November 8th 2024For the first time, Skyrizi has replaced Humira as AbbVie’s sales driver, largely due to companies encouraging “product hopping” to avoid competition, creating concerns for the sustainability of the burgeoning adalimumab biosimilar market.
Read More